The Swiss equity market slipped on Wednesday, with the benchmark SMI down 0.4% to 14,271 points as rising oil prices and mounting inflation concerns heightened expectations for tighter monetary policy.
The Mid-Cap SMIM index also retreated 0.4% to 3,081, while the broader SPI declined 0.4% to 20,077. Brent crude futures traded above $95 per barrel after renewed geopolitical tensions in the Middle East, fueling concerns over inflation and prompting speculation that both the European Central Bank and the U.S. Federal Reserve could raise interest rates in the coming weeks. The ECB is widely expected to hike rates next week, while a September increase by the Fed remains a high-probability scenario among investors.
Defensive stocks outperformed as investors sought shelter from volatility. Roche advanced 1.0%, while Swiss Life and Swisscom rose 0.4% and 0.8%, respectively. Novartis, however, lagged with a 0.4% decline after ceding ground to Roche following yesterday’s positive trial data. Nestlé fell 0.9% despite a $1.0 billion divestment agreement with Yellow Wood Partners for its mainstream vitamins, minerals and supplements business, a move analysts described as closing a "painful chapter of value destruction."
At the bottom of the leaderboard, Amrize slumped 4.0% after Bank of America downgraded the stock to Underperform from Neutral, while Holcim dropped 2.8%. Geberit and Sika, both construction-linked names, also declined 1.3%. Partners Group extended its losses with a 1.9% drop.
Technology shares led gains, with VAT up 3.2%, Comet up 3.1% and Inficon rising 0.9%. Traders cited a UBS study that raised price targets for all three stocks, alongside strong earnings from Dell. The sector remains sensitive to rising bond yields, as evidenced by the Nasdaq’s decline on Tuesday amid higher Treasury rates.
Bioversys surged 12.9% after the U.S. Food and Drug Administration granted Fast-Track designation to its antibiotic BV100. Newron Pharmaceuticals added 1.8% as it completed recruitment for the Phase III ENIGMA-TRS 1 study of its Evenamide candidate.
Montana Aerospace climbed 1.7% following leadership changes. VRP and major shareholder Michael Tojner assumed the role of Executive Chairman following the April departure of CEO Kai Arndt, while UBS initiated coverage with a Buy rating.
Sector performance showed divergence, with technology (+0.3%), real estate (+0.2%) and healthcare (+0.1%) among the few gainers. Basic materials (-1.6%) led decliners, pressured by Amrize’s drop, while utilities (-0.7%) and non-cyclical consumer goods (-0.9%) also lagged. Nestlé weighed on the latter category with a 0.7% decline.
European banks outperformed with a 0.5% gain, benefiting from elevated bond yields that support fixed-income revenue streams. Deutsche Bank rose 1.9%, Commerzbank gained 1.0%, ING advanced 1.9% and UBS added 0.5%. The gains followed a Goldman Sachs buy rating for Deutsche Bank.
Swiss equities mirrored broader global weakness, with the SMI down 0.4% to 14,280 points, the SMIM down 0.3% to 3,085 and the SPI down 0.3% to 20,084. Amrize remained the worst performer with a 2.7% drop after Bank of America’s downgrade, while Swiss Life and Roche led advancers with gains of 0.6% each.
